Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Non-Muscle Invasive Bladder Carcinoma Clear all
Withdrawn Phase 3 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
14
States / cities
Laguna Hills, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced May 21, 2026, 6:18 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-103
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
Polyphenon E, erlotinib hydrochloride, Erlotinib placebo, Polyphenon E
Dietary Supplement · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced May 21, 2026, 6:18 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
PLZ4-coated paclitaxel loaded micelles (PPM)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 6:18 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced May 21, 2026, 6:18 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer
Interventions
Sacituzumab tirumotecan, Rescue medication, Supportive care measures
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Bakersfield, California • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 6:18 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
STM-416
Drug
Lead sponsor
SURGE Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Gainesville, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions
Atezolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
269
States / cities
Daphne, Alabama • Mobile, Alabama • Scottsdale, Arizona + 201 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced May 21, 2026, 6:18 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
bevacizumab, cisplatin, gemcitabine hydrochloride, paclitaxel, cysectomy
Biological · Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
4
States / cities
Charleston, South Carolina • Florence, South Carolina • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced May 21, 2026, 6:18 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
TAR-200, Mitomycin C, Gemcitabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:18 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Transurethral Resection of Bladder Tumor, Gemcitabine
Biological · Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 21, 2026, 6:18 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
High-risk Non-muscle Invasive Bladder Cancer
Interventions
Pembrolizumab, BCG
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2034
U.S. locations
44
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer
Interventions
BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
98
States / cities
Little Rock, Arkansas • Los Angeles, California • Leesburg, Florida + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
BCG vaccine, recombinant interferon alfa
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced May 21, 2026, 6:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
Cabazitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
Guarionex J. Decastro
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Recurrent Bladder Cancer
Interventions
celecoxib, placebo
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Homewood, Alabama • Indianapolis, Indiana • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 21, 2026, 6:18 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Tampa, Florida • Iowa City, Iowa • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 6:18 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
nivolumab, Placebo, Bacillus Calmette-Guérin (BCG)
Drug · Other · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced May 21, 2026, 6:18 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
Genomic Health®, Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced May 21, 2026, 6:18 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced May 21, 2026, 6:18 PM EDT
Completed Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Transitional Cell Carcinoma of Bladder, Superficial Bladder Cancer
Interventions
Hyperthermia System, Mitomycin C
Device · Drug
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced May 21, 2026, 6:18 PM EDT